Hospital

Although the research focused on Black communities in the United States, there is also evidence linking racism and blood pressure for patients who are Asian or Hispanic.

Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Digital therapeutics (DTx), a novel evidence-based software approach, is revolutionizing health care by delivering personalized treatments. Pharmacovigilance ensures DTx safety but faces challenges such as data privacy and standardization.

Inhaling smoke can have acute effect for people with asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.

Tucatinib is an oral HER2-targeting tyrosine kinase inhibitor that was approved by the FDA in 2020.

Presence of comorbidities in older patients with breast cancer complicates treatment decisions.

Rates of invasive breast cancer or death were 50% lower with adjuvant trastuzumab emtansine compared with trastuzumab alone.

Pharmacists can play an important role in tobacco cessation.

Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).

Endocrine-immune-based therapies yielded favorable objective response rates but had limited impact on pathological complete response.

These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.

The report highlights perspective from 4 key stakeholders of patients, specialty pharmacies and providers, biopharmaceutical industry, and public and private payers.

Abelacimab (Anthos Therapeutics Inc) is a novel factor XI inhibitor being investigated for the reduction of bleeding for patients with atrial fibrillation.

USP provides health literacy standards and solutions that enhance medication safety and improve patient outcomes.

The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.

The drug is being investigated as a PET diagnostic of cardiac amyloid light-chain and amyloid transthyretin-related (ATTR) amyloidosis.

This case report depicts a probable infusion reaction in a 61-year-old woman prescribed evinacumab for the treatment of familial hypercholesterolemia.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

Stem cell transplantation rates increased the longer patients remained on therapy for myelofibrosis.

Vusolimogene oderparepvec in combination with nivolumab is being assessed to treat individuals with unresectable or metastatic stage IIIb-IV cutaneous melanoma.

The caps on insulin and yearly out-of-pocket drug costs remain unaffected by this decision.

Regardless of confounding factors, the ratio of high-sensitivity C-reactive protein to high-density lipoprotein cholesterol predicts the all-cause long-term mortality.

An infusion and specialty clinical pharmacist is a valuable integrated member of the health care team as demonstrated by cost avoidance and high satisfaction reported by both veterans and specialty providers.

Pharmacists play a significant role in managing gout by educating patients about the disease and ensuring proper medication adherence to urate-lowering therapy.

Pharmacists ensure responsible antibiotic use, combating resistance through tailored therapies.

At the start of 2025, 590 drug prices changed, with only 7 drugs seeing decreases in wholesale acquisition costs (WAC).

A series of patient cases demonstrates the potential harm that patients with chronic inflammatory demyelinating polyneuropathy (CIDP) may face when transitioning from intravenous immunoglobulin (IVIG) to FcRn therapy.

The international cohort study evaluated the safety, efficacy of BCMA-targeting agents ciltacabtagene autoleucel and idecabtagene vicleucel.